Predictive value of NRI, NLR, PLR and LMR for therapeutic efficacy and prognosis in advanced rectal cancer patients treated with PD-1/PD-L1 immunotherapy - Summary - MDSpire

Predictive value of NRI, NLR, PLR and LMR for therapeutic efficacy and prognosis in advanced rectal cancer patients treated with PD-1/PD-L1 immunotherapy

  • By

  • Mengli Gao

  • Zhe Gao

  • Yanan Wang

  • Wenguang Song

  • May 28, 2026

  • 0 min

Share

Objective:

To investigate the predictive value of NRI, NLR, PLR, and LMR for the prognosis and effectiveness of immunotherapy in patients with advanced rectal cancer.

Key Findings:
  • Optimal cut-off values: NLR 2.50, PLR 142.23, LMR 3.92, NRI 50.45.
  • Higher ORR and DCR in low NLR, low PLR, high LMR, and high NRI groups (all P < 0.05).
  • High NLR and high PLR associated with shorter median PFS and OS (all P < 0.001).
  • Independent risk factors for shortened PFS: TNM stage IV (HR = 2.014), high NLR (HR = 2.689).
  • Independent risk factors for shortened OS: TNM stage IV (HR = 1.923), poorly differentiated tumor (HR = 1.786), high NLR (HR = 2.519).
Interpretation:

Remove unsupported claims and conclusions.

Limitations:
  • Retrospective design may introduce bias.
  • Single-center study limits generalizability.
Conclusion:

Remove unsupported claims and conclusions.

Original Source(s)

Predictive value of NRI, NLR, PLR and LMR for therapeutic efficacy and prognosis in advanced rectal cancer patients treated with PD-1/PD-L1 immunotherapy

  • by Mengli Gao, Zhe Gao, Yanan Wang, Wenguang Song

  • May 28, 2026

Related Content

Machine learning-based identification of an oxidative phosphorylation signature for prognosis, immune infiltration, and drug sensitivity in ovarian cancer

Effect of aesthetic nursing interventions on the health-related quality of life of cervical cancer patients after treatment

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship